菜单
Rules out hypothyroidism as a secondary cause of hyperlipidemia prior to initiating lipid-lowering therapy. Triggered by patient presentation with hyperlipidemia, consideration of starting lipid-lowering medication, or assessment of secondary causes of dyslipidemia.
默认使用会先检查来源的 Prompt；你也可以切换为直接命令，或下载本地副本。
决定是否安装前，请先阅读 SKILL.md，以及 SkillsMP 当前展示的配套文件。
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
直接命令不会经过审查 Prompt；运行前请先检查来源。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill endo-rule-out-hypothyroidism-before-lipid-treatment命令会保持在同一行。复制前请横向滚动并检查完整内容。
想先保存到本地？可下载 SkillsMP 当前能够提供的文件。
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
基于 SOC 职业分类
正在显示 SKILL.md
| name | endo-rule-out-hypothyroidism-before-lipid-treatment |
| description | Rules out hypothyroidism as a secondary cause of hyperlipidemia prior to initiating lipid-lowering therapy. Triggered by patient presentation with hyperlipidemia, consideration of starting lipid-lowering medication, or assessment of secondary causes of dyslipidemia. |
Order serum TSH to evaluate for hypothyroidism as a potential cause of hyperlipidemia.
If TSH is within normal limits, rule out hypothyroidism as the cause of hyperlipidemia; if TSH is elevated, rule in hypothyroidism.
If hypothyroidism is ruled in (TSH elevated), classify as overt (TSH ≥10 mIU/L) or subclinical (TSH between upper limit of normal and 10 mIU/L).
If hypothyroidism is confirmed (overt or subclinical with associated hyperlipidemia), initiate levothyroxine therapy and reassess lipid panel after euthyroidism before considering lipid-lowering treatment.
Do not initiate lipid-lowering therapy without first ruling out hypothyroidism, as treating the thyroid disorder may resolve hyperlipidemia and avoid unnecessary medication; mimics include other secondary causes (e.g., nephrotic syndrome, medications) but hypothyroidism is a common and treatable cause.
A 55-year-old woman with new hyperlipidemia (LDL-C 190 mg/dL, TG 220 mg/dL) and fatigue has TSH 12.5 mIU/L; after levothyroxine normalization, lipids improve to LDL-C 110 mg/dL, TG 150 mg/dL, avoiding statin initiation.
Source: Lipid Management in Patients with Endocrine Disorders, Endocrine Society, 2020, doi:10.1210/clinem/dgaa674